Products

CISLIEVA 10 MG Injection (Cisplatin): A Fundamental Platinum-Based Therapy for Precision Oncology CISLIEVA 10 MG Injection is a highly potent antineoplastic agent featuring the active pharmaceutical ingredient Cisplatin. As a first-generation platinum-based chemotherapeutic agent, Cisplatin remains one of the most effective and widely utilized drugs in the global fight against various solid tumors.. The 10mg dosage is a critical strength used for precise titration, allowing oncologists to design customized treatment cycles that balance therapeutic efficacy with patient safety. Therapeutic Indications and Clinical Scope Metastatic Testicular Tumors: A primary component of combination therapy in patients who have already received appropriate surgical or radiotherapeutic procedures. Metastatic Ovarian Tumors: Indicated as secondary therapy in patients who have already received but failed standard chemotherapy, or as a first-line agent in combination with other approved drugs. Advanced Bladder Cancer: Used as a single agent or in combination for patients with transitional cell bladder cancer that is no longer amenable to local treatments. Head and Neck Cancers: Frequently employed in chemotherapy regimens for squamous cell carcinomas of the head and neck. Cervical Cancer: Used in conjunction with radiation therapy or other chemotherapeutic agents for advanced stages. Mechanism of Action: How CISLIEVA 10 MG Works Cellular Entry: Once the drug enters the cell, it loses its chloride atoms and becomes a positively charged molecule. DNA Binding: The activated platinum complex binds to the nitrogen atoms of the DNA bases (specifically guanine and adenine). Intrastand Cross-Linking: It creates “kinks“ or cross-links within the DNA strands. Inhibition of Synthesis: These structural changes make it impossible for the DNA to unwind or replicate. Programmed Cell Death: The DNA damage triggers a cellular response that leads to apoptosis (programmed cell death), halting tumor growth and preventing metastasis. Professional Administration and Safety Guidelines Route: Administered strictly via Intravenous (IV) Infusion. Hydration Protocol: To minimize the risk of nephrotoxicity (kidney damage), patients must receive adequate pre-treatment and post-treatment hydration (usually 1 to 2 liters of fluid). Clinical Environment: This medication must be administered by trained oncology professionals in a setting equipped for continuous monitoring. Precise Titration: The 10mg strength facilitates accurate dosing for pediatric cases or for patients requiring gradual dose escalation . Safety Profile and Professional Monitoring Nephrotoxicity Monitoring: Regular monitoring of serum creatinine, BUN, and creatinine clearance is mandatory. Ototoxicity Checks: Patients should undergo periodic hearing tests (audiograms), as Cisplatin can cause cumulative and permanent hearing loss. Hematological Vigilance: Regular Complete Blood Counts (CBC) are essential to monitor for bone marrow suppression (anemia, neutropenia, and thrombocytopenia). Electrolyte Balance: Monitoring of serum magnesium, potassium, and calcium levels is required to prevent imbalances. Neurotoxicity Monitoring: Vigilance for signs of peripheral neuropathy (numbness or tingling in extremities). Storage and Global Handling Instructions Temperature: Store at controlled room temperature (20°C to 25°C). Do not refrigerate or freeze, as precipitation may occur. Protection: Keep the vial in the original carton to protect it from light. Cytotoxic Handling: As a hazardous antineoplastic agent, CISLIEVA 10 MG must be prepared and handled by trained professionals using appropriate PPE (Personal Protective Equipment) and disposed of according to international biohazard protocols. Why Choose Ernest Oncology? 100% Genuine Medication: We source directly from GMP-certified channels, ensuring every vial is authentic with an optimal shelf life. Specialized Logistics Precision: Our team manages pharmaceutical exports with expertise, utilizing secure packaging and efficient transit routes to maintain product stability. Regulatory & Documentation Support: We handle all necessary paperwork, including Certificates of Analysis (CoA) and export permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support oncology hospitals, pharmacy networks, and government health programs worldwide. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

CARBOLIEVA 450 MG Injection (Carboplatin): High-Strength Platinum-Based Therapy for Advanced Oncology CARBOLIEVA 450 Injection is a maximum-strength antineoplastic medication featuring the active pharmaceutical ingredient Carboplatin. As a specialized second-generation platinum-based chemotherapeutic agent, it is a critical pillar in the systemic treatment of various solid tumors. The 450mg concentration is specifically designed for high-volume clinical settings, allowing for efficient administration in intensive chemotherapy regimens while maintaining a superior safety profile compared to older platinum analogs. Therapeutic Indications and Global Clinical Usage Advanced Ovarian Carcinoma: Used as a primary first-line treatment (often in combination with taxanes) and for recurrent ovarian cancer. Small Cell Lung Cancer (SCLC): A frontline component in combination chemotherapy for both limited and extensive-stage disease. Non-Small Cell Lung Cancer (NSCLC): Utilized in palliative and adjuvant settings for advanced lung malignancies. Head and Neck Squamous Cell Carcinomas: Employed in various specialized treatment cycles for advanced tumors. Germ Cell Tumors: Effective in the treatment of seminomatous and non-seminomatous germ cell malignancies. Mechanism of Action: How CARBOLIEVA 450 Works Cellular Activation: Once administered, Carboplatin slowly undergoes a process of aquation within the cell. DNA Binding: The activated platinum complex binds to the DNA bases of the cancer cell, specifically forming inter-strand and intra-strand cross-links. Structural Disruption: These cross-links physically prevent the DNA from unwinding, which is necessary for replication and protein synthesis. Mitotic Catastrophe: Unable to repair the DNA or replicate, the cancer cell’s growth is halted at the G2 phase, leading to programmed cell death (apoptosis). Professional Administration and Dosage Route: Administered exclusively via Intravenous (IV) Infusion. Precision Dosing (Calvert Formula): Unlike standard chemotherapy, the dose of CARBOLIEVA 450 is frequently calculated using the Calvert Formula. This determines the dose based on the patient's renal function (GFR) and a target Area Under the Curve (AUC), ensuring maximum efficacy with minimized toxicity. Infusion Time: Typically administered over 15 to 60 minutes. Cycle Interval: Generally prescribed in cycles of once every 3 to 4 weeks to allow for bone marrow recovery. Safety Profile and Clinical Monitoring Hematological Vigilance: The dose-limiting factor is myelosuppression (anemia, neutropenia, and thrombocytopenia). Frequent Complete Blood Counts (CBC) are mandatory. Renal Function Monitoring: Periodic creatinine clearance tests ensure the patient can safely eliminate the drug. Electrolyte Balance: Monitoring levels of magnesium, potassium, and calcium is standard clinical practice. Hypersensitivity: While rare, monitoring for infusion-related allergic reactions is essential during the initial administration. Storage and Global Handling Instructions Temperature: Store at controlled room temperature (20°C to 25°C) and protect from light. Handling: As a hazardous cytotoxic agent, CARBOLIEVA 450 must be prepared and handled by trained professionals using appropriate PPE and disposed of according to biohazard protocols. Why Choose Ernest Oncology? 100% Genuine Medication: We source directly from GMP-certified channels, ensuring every vial is authentic with an optimal shelf life. Global Export Footprint: We facilitate secure and rapid shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Specialized Logistics Precision: Our team manages pharmaceutical exports with expertise, utilizing secure packaging and efficient transit to preserve drug stability. Regulatory & Documentation Support: We handle all necessary paperwork, including Certificates of Analysis (CoA) and permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support oncology hospitals, pharmacy networks, and government health departments. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

CARBOLIEVA 150 MG Injection (Carboplatin): Precision Alkylating Agent for Advanced Oncology CARBOLIEVA 150 Injection is a potent antineoplastic medication featuring the active pharmaceutical ingredient Carboplatin. As a second-generation platinum-based chemotherapeutic agent, it is a cornerstone in the treatment of various solid tumors. Manufactured to meet international quality standards, CARBOLIEVA 150 is designed to offer a more favorable safety profile compared to its predecessor, cisplatin, particularly regarding renal and neurological toxicity. Therapeutic Indications and Clinical Usage Ovarian Carcinoma: Both as a first-line therapy (often in combination with paclitaxel) and as a secondary treatment for recurrent disease. Small Cell Lung Cancer (SCLC): A primary component in combination regimens for limited and extensive-stage lung cancer. Non-Small Cell Lung Cancer (NSCLC): Used in palliative and adjuvant settings for advanced lung malignancies. Head and Neck Cancers: Employed in the treatment of various squamous cell carcinomas. Cervical and Bladder Cancer: Often used when aggressive platinum-based intervention is required. Mechanism of Action: How CARBOLIEVA 150 Works Activation: Once inside the cell, Carboplatin undergoes a slow activation process where it reacts with water. DNA Cross-Linking: The activated molecules bind to the DNA strands of the cancer cell, creating “cross-links“ (both intra-strand and inter-strand). Replication Blockade: These cross-links change the structure of the DNA, making it impossible for the cell to copy its genetic material or repair itself. Apoptosis: The cell-cycle arrest eventually triggers programmed cell death (apoptosis), effectively halting the progression of the tumor. Professional Administration and Dosage Route: Administered strictly via Intravenous (IV) Infusion. Calvert Formula: Unlike many drugs, the dosage for CARBOLIEVA is often calculated using the Calvert Formula, which determines the dose based on the patient’s target area under the Curve (AUC) and glomerular filtration rate (GFR). Infusion Time: Typically administered over 15 to 60 minutes depending on the specific clinical protocol. Cycle Frequency: Usually administered once every 3 to 4 weeks, allowing the patient's bone marrow time to recover between treatments. Safety Profile and Clinical Monitoring Myelosuppression: The primary dose-limiting factor is bone marrow suppression (anemia, neutropenia, and thrombocytopenia). Regular Complete Blood Counts (CBC) are mandatory. Renal Function: While less nephrotoxic than cisplatin, monitoring of creatinine clearance remains essential. Electrolyte Balance: Periodic checks for magnesium, potassium, and calcium levels. Ototoxicity: Periodic hearing tests may be required for patients on long-term or high-dose therapy. Storage and Global Handling Storage: Store at controlled room temperature (20°C to 25°C) and protect from light. Handling: As a cytotoxic agent, CARBOLIEVA must be handled using specialized safety equipment (PPE) and disposed of according to biohazard protocols for hazardous drugs. Why Choose Ernest Oncology? 100% Genuine Medication: We source directly from GMP-certified channels, ensuring every vial is authentic with an optimal shelf life. Global Distribution Reach: Secure and rapid export to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Specialized Logistics Expertise: Our team manages pharmaceutical exports with precision, utilizing secure packaging and efficient transit to preserve drug stability. Regulatory & Documentation Support: We handle all necessary export paperwork, including Certificates of Analysis (CoA) and permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support oncology hospitals, pharmacy networks, and government health programs. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: [exports@ernestpharmaceuticals.com] 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

NABPACLIEVA 100 MG Injection (Nab-Paclitaxel): Advanced Albumin-Bound Nanotechnology in Oncology NABPACLIEVA 100 MG Injection represents a significant technological leap in chemotherapy, featuring the active pharmaceutical ingredient Nab-Paclitaxel (Nanoparticle Albumin-Bound Paclitaxel). Unlike traditional paclitaxel, which requires solvent-based delivery, NABPACLIEVA utilizes cutting-edge nanotechnology to bind paclitaxel to human albumin. This specialized delivery system enhances the drug's solubility, improves its safety profile, and allows for higher doses to be delivered directly to the tumor microenvironment. Therapeutic Indications and Global Usage Metastatic Breast Cancer: Indicated for patients who have failed prior chemotherapy for metastatic disease or have experienced a relapse within six months of adjuvant chemotherapy. Non-Small Cell Lung Cancer (NSCLC): Used as a first-line treatment in combination with carboplatin for patients with locally advanced or metastatic NSCLC who are not candidates for curative surgery or radiation. Metastatic Adenocarcinoma of the Pancreas: Often used as a first-line treatment in combination with gemcitabine to improve survival outcomes. Advanced Ovarian Cancer: Frequently utilized in specialized treatment cycles where solvent-free paclitaxel is preferred. The Mechanism: Nanoparticle Albumin-Bound (nab) Technology Albumin-Mediated Transport: Cancer cells often overexpress SPARC (Secreted Protein Acidic and Rich in Cysteine), a protein that binds to albumin. NABPACLIEVA exploits this biological pathway to “pull“ the chemotherapy directly into the tumor. Solvent-Free Delivery: Traditional paclitaxel uses Cremophor EL, which often causes severe allergic reactions. NABPACLIEVA is solvent-free, significantly reducing the risk of infusion-related hypersensitivity.Enhanced Penetration: The nanoparticles (approximately 130 nanometers) facilitate better penetration through the endothelial cell wall and into the tumor tissue. Microtubule Inhibition: Once inside the cell, it works by stabilizing microtubules, preventing the cancer cell from dividing and eventually inducing apoptosis (cell death). Dosage and Administration Guidelines Route: Administered solely via Intravenous (IV) Infusion. Standard Regimen: Typically administered over 30 minutes, which is significantly faster than the 3-hour infusion required for standard paclitaxel. Cycle Frequency: Depending on the indication, it is often administered on Days 1, 8, and 15 of a 21-day or 28-day cycle. Dose Modifications: Oncologists may adjust the 100mg dosage based on the patient's body surface area (BSA) and hematological tolerance. Safety Profile and Clinical Monitoring Myelosuppression: Regular monitoring of Complete Blood Counts (CBC) is essential to manage potential neutropenia (low white blood cell count). Peripheral Neuropathy: Checking for sensory disturbances such as tingling or numbness in the hands and feet. Hepatic Health: Periodic liver function tests (LFTs) are mandatory for safety and efficacy. Fatigue & Gastrointestinal Effects: Managing common side effects like tiredness, nausea, and mild joint pain. Storage and Global Handling Storage: Store the un-reconstituted vial at room temperature (20°C to 25°C) in the original carton to protect it from light. Reconstitution: Once reconstituted, the suspension should be used within the clinical stability window defined by the manufacturer. Why Choose Ernest Oncology? 100% Genuine Supply: We source products directly from GMP-certified channels, ensuring every vial is authentic with an optimal shelf life. Verified Export Network: We facilitate rapid and secure shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Cold Chain & Specialized Logistics: Our team manages pharmaceutical exports with precision, ensuring the integrity of the nanoparticle formulation during international transit. Regulatory & Documentation Excellence: We handle all necessary export paperwork, including Certificates of Analysis (CoA) and permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support oncology hospitals, clinics, and government health programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

Falsolieva 250mg Injection (Fulvestrant): Targeted Endocrine Therapy for Advanced Breast Cancer Falsolieva 250 mg Injection is a specialized hormonal therapy containing the active ingredient Fulvestrant. It belongs to a class of medications known as selective estrogen receptor degraders (SERDs). Unlike traditional hormone therapies that merely block estrogen, Falsolieva works by significantly reducing the number of estrogen receptors in the body, providing a powerful intervention for hormone-receptor-positive (HR+) malignancies. Manufactured to meet global quality standards, Falsolieva is a critical tool for oncologists managing postmenopausal breast cancer. Therapeutic Indications: Clinical Scope HR-Positive Metastatic Breast Cancer: For postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer not previously treated with endocrine therapy. Progressive Advanced Breast Cancer: For women whose disease has progressed following anti-estrogen therapy (such as tamoxifen or aromatase inhibitors). Combination Therapy: Often used in combination with targeted therapies like CDK4/6 inhibitors (e.g., Palbociclib, Abemaciclib) to enhance clinical outcomes in metastatic settings. Mechanism of Action: How Falsolieva Works Competitive Binding: Fulvestrant binds to estrogen receptors (ER) with an affinity significantly higher than that of tamoxifen. Receptor Degradation: Once bound, it causes the estrogen receptor to change shape, leading to the degradation and eventual destruction of the receptor protein. Transcriptional Blockade: By reducing the number of available receptors, it prevents estrogen from “locking“ into the cancer cell, effectively stopping the signals that trigger tumor growth. No Agonist Effects: Unlike some other therapies, Falsolieva has no estrogen-mimicking effects, making it a pure antagonist. Professional Administration and Dosage Route of Administration: Falsolieva is administered as a slow intramuscular (IM) injection into the buttocks (gluteal area). Standard Dosing Regimen: The recommended dose is 500mg (administered as two 250mg injections, one in each buttock). Schedule: Typically administered on days 1, 15, and 29 of the first month, followed by once-monthly maintenance doses. Clinical Setting: Due to the specialized nature of the injection, it must be administered by a healthcare professional. Safety Profile and Patient Monitoring Injection Site Reactions: Temporary pain, inflammation, or bruising at the site of the IM injection. Hormonal Symptoms: Hot flashes, bone pain, and nausea are common but usually manageable. Hepatic Function: Liver function tests (LFTs) are recommended for patients with known hepatic impairment, as the drug is metabolized in the liver. Thromboembolic Events: While rare, monitoring for signs of blood clots is standard clinical practice for hormonal therapies. Why Choose Ernest Oncology? 100% Genuine Supply: We source Falsolieva directly from GMP-certified channels, ensuring every batch is authentic with an optimal shelf life. Global Distribution Reach: Secure and rapid shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Temperature-Controlled Logistics: Our team is expert in handling sensitive oncology products, ensuring they reach their destination under the required storage conditions. Regulatory & Documentation Support: We handle all necessary export paperwork, including Certificates of Analysis (CoA) and permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support oncology hospitals and pharmacy networks worldwide. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: [exports@ernestpharmaceuticals.com] 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

Docelieva RTU Injection 120mg (Docetaxel): High-Dose Ready-To-Use Cytotoxic Therapy Docelieva RTU (Ready-To-Use) 120 mg Injection is a maximum-strength antineoplastic formulation containing Docetaxel. As a highly potent member of the taxane family, Docetaxel is globally recognized as a critical intervention for advanced and metastatic malignancies. The “Ready-To-Use“ (RTU) technology eliminates the need for initial dilution steps, significantly reducing preparation time in oncology pharmacies and minimizing the risk of dosing errors or contamination. Therapeutic Indications: Global Clinical Applications Metastatic Breast Cancer: Indicated for patients whose cancer has progressed after initial chemotherapy or where high-dose taxane therapy is required. Non-Small Cell Lung Cancer (NSCLC): Used as a primary first-line treatment in combination with platinum-based agents or as a second-line therapy for locally advanced or metastatic cases. Metastatic Castration-Resistant Prostate Cancer (mCRPC): Administered in combination with prednisone to improve survival rates and quality of life. Advanced Gastric Adenocarcinoma: Employed in combination protocols for metastatic gastric cancer, including the gastroesophageal junction. Squamous Cell Carcinoma of the Head and Neck (SCCHN): Utilized in induction treatment for locally advanced stages. Mechanism of Action: How Docelieva RTU 120mg Works Tubulin Binding: Docetaxel binds with high affinity to the beta-tubulin subunit of the cell's microtubules. Structural Stabilization: It promotes the assembly of microtubules while simultaneously inhibiting their disassembly (depolymerization). Mitotic Blockade: Because the microtubules are “frozen“ in place, the cancer cell cannot form the mitotic spindle required for division. Apoptosis: The resulting cell-cycle arrest at the G2/M phase triggers programmed cell death (apoptosis), halting tumor progression and the spread of metastasis. Professional Administration & Safety Guidelines Pre-medication Protocol: To reduce the risk of severe hypersensitivity reactions and fluid retention, patients are typically pre-treated with oral corticosteroids (e.g., dexamethasone) starting 24 hours prior to infusion. Clinical Monitoring: Continuous monitoring of vital signs is essential during the infusion, especially for signs of anaphylaxis, hypotension, or severe skin reactions. Hepatic Caution: This medication is contraindicated in patients with severe hepatic impairment, as decreased clearance significantly increases the risk of life-threatening toxicity. Safety Profile and Clinical Vigilance Neutropenia: Regular monitoring of a complete blood count (CBC) is mandatory to track white blood cell levels. Peripheral Neuropathy: Checking for sensory disturbances such as tingling or numbness in extremities. Fluid Retention: Monitoring for weight gain, peripheral edema, or pleural effusion. Dermatological Reactions: Watching for severe skin rashes or nail changes. Why Choose Ernest Oncology? 100% Genuine Medication: We source directly from GMP-certified facilities, ensuring product authenticity and maximum shelf life. Extensive Global Network: Secure and rapid shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Logistics Precision: Our team specializes in the export of cytotoxic agents, utilizing specialized packaging to maintain product stability during long-distance transit. Regulatory & Documentation Support: We handle all necessary paperwork, including Certificates of Analysis (CoA) and export permits, for seamless customs clearance. Wholesale Bulk Supply: We offer competitive pricing for hospitals, government health departments, and oncology centers worldwide. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

Docelieva RTU Injection 80mg (Docetaxel): High-Potency Cytotoxic Therapy for Advanced Oncology Docelieva RTU (Ready-To-Use) 80 mg Injection is a maximum-strength chemotherapeutic agent featuring the active pharmaceutical ingredient Docetaxel. As a key member of the taxane family, Docetaxel is globally recognized as a cornerstone in the treatment of various aggressive and metastatic malignancies. The “Ready-To-Use“ (RTU) formulation is specifically engineered for clinical efficiency, reducing preparation time and the risk of contamination in high-volume oncology centers. Therapeutic Indications: Global Clinical Applications Breast Cancer: Used as an adjuvant treatment for operable node-positive disease and for the management of locally advanced or metastatic breast cancer after the failure of prior chemotherapy. Non-Small Cell Lung Cancer (NSCLC): Indicated for patients with locally advanced or metastatic NSCLC, either as a single agent or in combination with platinum-based therapies. Prostate Cancer: A primary treatment for metastatic castration-resistant prostate cancer (mCRPC) when administered in conjunction with prednisone. Gastric Adenocarcinoma: Employed in combination with cisplatin and 5-fluorouracil for advanced gastric cancer, including the gastroesophageal junction. Head and Neck Cancer: Used in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Mechanism of Action: How Docelieva RTU 80mg Works Microtubule Binding: Docetaxel binds to the beta-tubulin subunits within the cancer cell's cytoskeleton. Stabilization vs. Disassembly: Unlike many other agents, it promotes the assembly of microtubules while simultaneously preventing their disassembly (depolymerization). Mitotic Blockade: This stabilization “freezes“ the mitotic spindle. Because the cancer cell cannot reorganize its internal structure, it is unable to complete mitosis (cell division). Apoptosis: The resulting cell-cycle arrest triggers programmed cell death (apoptosis), effectively inhibiting tumor growth and preventing further metastasis. Administration and Professional Safety Guidelines Pre-medication Protocol: To reduce the incidence and severity of fluid retention and hypersensitivity reactions, patients are typically pre-treated with oral corticosteroids (such as dexamethasone) starting one day prior to the infusion. Infusion Monitoring: Clinical teams must closely monitor vital signs during the infusion for signs of anaphylaxis or severe skin reactions. Dose Adjustments: Dosing is calculated based on Body Surface Area (BSA) and may be adjusted by the oncologist based on hematological response and patient tolerability. Safety Profile and Clinical Vigilance Neutropenia: Regular blood counts are essential to monitor white blood cell levels, as myelosuppression is a known side effect. Fluid Retention: Monitoring for peripheral edema or pleural effusion. Peripheral Neuropathy: Checking for sensory disturbances like tingling or numbness in the hands and feet. Hepatic Function: Liver function tests (LFTs) are mandatory, as impaired liver function significantly increases the risk of toxicity. Why Choose Ernest Oncology? 100% Genuine Supply: We source Docelieva directly from GMP-certified channels, ensuring every vial is authentic with an optimal shelf life. Extensive Global Reach: We facilitate secure and rapid shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Specialized Logistics: Our team manages pharmaceutical exports with precision, utilizing secure packaging and efficient transit routes to maintain product stability. Regulatory & Documentation Support: We handle all necessary export paperwork, including Certificates of Analysis (CoA) and permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support hospitals, oncology centers, and government health departments worldwide. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites: www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

Docelieva RTU Injection 20mg (Docetaxel): Advanced Cytotoxic Therapy for Global Oncology Docelieva RTU (Ready-To-Use) 20 mg Injection is a sophisticated chemotherapeutic agent containing the active pharmaceutical ingredient Docetaxel. As a member of the taxane family, Docetaxel is a cornerstone of modern oncological treatment, prized for its ability to target and neutralize rapidly dividing malignant cells. Manufactured to international standards, Docelieva RTU is designed for precise, efficient administration in clinical settings, making it a preferred choice for oncology centers worldwide. Therapeutic Indications: Broad Spectrum Cancer Management Breast Cancer: Used both as adjuvant treatment for operable node-positive/negative breast cancer and as a therapy for locally advanced or metastatic breast cancer. Non-Small Cell Lung Cancer (NSCLC): A critical treatment for patients with locally advanced or metastatic disease, often used where previous chemotherapy has failed or as a first-line combination therapy. Prostate Cancer: Indicated in combination with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer and hormone-sensitive prostate cancer. Gastric Adenocarcinoma: Used in combination with cisplatin and 5-fluorouracil for patients with metastatic gastric or gastroesophageal junction adenocarcinoma. Head and Neck Cancer: Employed in induction treatment protocols for locally advanced squamous cell carcinoma. Mechanism of Action: How Docelieva RTU Works Binding to Beta-Tubulin: The drug binds with high affinity to the beta-tubulin subunit of the cell's cytoskeleton. Stabilization of Microtubules: It promotes the polymerization of tubulin, preventing the natural disassembly (depolymerization) of microtubules. Mitotic Arrest: By freezing the cell’s internal machinery, it prevents the mitotic spindle from functioning properly. This “locks“ the cancer cell in the metaphase of division. Apoptosis (Programmed Cell Death): Because the cell cannot complete division, it triggers a cascade leading to programmed cell death, effectively reducing tumor size and halting cancer spread. Professional Administration & Safety Guidelines Pre-medication Protocol: To manage potential hypersensitivity reactions (such as fluid retention, rash, or breathing difficulties), a standard pre-medication regimen—typically involving oral corticosteroids like dexamethasone—is required before the infusion. Professional Oversight: Clinical teams must monitor patients for potential side effects, including neutropenia (low white blood cell count), fatigue, peripheral neuropathy, and gastrointestinal reactions. Handling: As a cytotoxic agent, strict safety protocols (PPE) must be followed during handling and disposal. Why Choose Ernest Oncology? 100% Genuine Medication: We source Docelieva RTU directly from GMP-certified channels, ensuring every batch is authentic with an optimal shelf life. Global Export Footprint: Our established supply chain ensures rapid, secure transit to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Specialized Logistics Expertise: We utilize pharmaceutical-grade packaging and efficient transit routes to maintain product stability, essential for sensitive cytotoxic injections. Regulatory & Documentation Support: We handle all necessary export documentation, including Certificates of Analysis (CoA) and required permits, ensuring seamless customs clearance for your medical facility. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support oncology hospitals, pharmacy networks, and government health departments. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

PACLIEVA 300 MG Injection (Paclitaxel): Maximum-Strength Cytotoxic Therapy for Advanced Oncology PACLIEVA 300 MG Injection is a high-dose, professional-grade antineoplastic formulation containing Paclitaxel. As a member of the taxane family, Paclitaxel is one of the most effective and widely utilized chemotherapy agents in the global fight against advanced solid tumors. Manufactured by Zuventus Healthcare, the 300mg vial provides the high-concentration volume required for intensive systemic treatment, particularly for patients requiring large-scale dosing based on body surface area (BSA). Therapeutic Indications and Global Clinical Usage Metastatic Breast Cancer: Indicated for patients who have failed prior chemotherapy or require aggressive intervention for advanced disease. Advanced Ovarian Cancer: Frequently used as first-line therapy in combination with platinum-based compounds (Cisplatin/Carboplatin). Non-Small Cell Lung Cancer (NSCLC): A cornerstone treatment for advanced stages of lung cancer in patients who are not candidates for surgery. Refractory Kaposi’s Sarcoma: Specifically utilized as a second-line treatment for AIDS-related Kaposi's sarcoma. The Science of PACLIEVA: Mechanism of Action Binding to Tubulin: Paclitaxel binds to the beta-subunit of tubulin, a protein essential for cell structure. Structural “Freezing“: Unlike other agents that prevent microtubule formation, PACLIEVA promotes the assembly of microtubules but prevents them from breaking down (disassembling). Mitotic Blockade: By stabilizing the mitotic spindle, the cancer cell becomes unable to complete its division (mitosis). Induced Apoptosis: The resulting cell-cycle arrest triggers programmed cell death (apoptosis), inhibiting tumor progression and metastasis. Administration and Dosage Protocols Route: Administered strictly via Intravenous (IV) Infusion. Preparation: Must be diluted with 0.9% Sodium Chloride or 5% Dextrose to a final concentration of 0.3 to 1.2 mg/mL. Pre-medication Requirement: To prevent severe hypersensitivity reactions (HSRs), patients are pre-treated with corticosteroids (Dexamethasone), H1 antagonists (Diphenhydramine), and H2 antagonists. Clinical Environment: This high-strength injection must be administered by qualified oncology professionals in a facility equipped to manage anaphylactic reactions. Safety Profile and Professional Monitoring Hematological Monitoring: Regular blood counts are mandatory to monitor for neutropenia (low white blood cell count), the primary dose-limiting toxicity. Neurotoxicity Check: Monitoring for peripheral neuropathy, which manifests as numbness or tingling in the extremities. Hepatic Vigilance: Liver function tests (LFTs) ensure the patient can safely metabolize high doses of Paclitaxel. Cardiovascular Stability: Monitoring for bradycardia or hypotension during the initial hours of infusion. Storage and Global Handling Instructions Storage: Keep in the original carton at controlled room temperature (20°C to 25°C) to protect the vial from light. Cytotoxic Handling: As a hazardous antineoplastic agent, PACLIEVA should be handled using specialized safety equipment (PPE) and disposed of according to international biohazard protocols. Why Choose Ernest Oncology Global? 100% Genuine Supply: We source directly from GMP-certified manufacturers, guaranteeing authentic medication with optimal shelf life. Global Distribution Network: Secure and rapid shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Professional Regulatory Support: Our team handles all export documentation, including Certificates of Analysis (CoA) and necessary permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to support hospitals, oncology clinics, and government health departments worldwide. Specialized Logistics: We utilize industry-standard packaging to maintain product stability and integrity during long-distance transit. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: [exports@ernestpharmaceuticals.com] 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

PACLIEVA 260 MG Injection (Paclitaxel): High-Dose Chemotherapeutic Solution for Advanced Oncology PACLIEVA 260 MG Injection is a maximum-strength antineoplastic formulation containing Paclitaxel, a potent taxane-derived cytotoxic agent. This high-concentration injection is specifically engineered for the intensive treatment of advanced, metastatic, or refractory solid tumors. Manufactured by Zuventus Healthcare, PACLIEVA 260 MG is a cornerstone in international oncology protocols, providing clinicians with the necessary strength for high-dose systemic chemotherapy. Therapeutic Indications and Global Clinical Usage Advanced Ovarian Cancer: Used as primary therapy for advanced carcinoma and for patients who have failed prior platinum-based treatments. Metastatic Breast Cancer: Indicated for patients whose disease has progressed despite standard anthracycline therapy or where combination chemotherapy is required. Non-Small Cell Lung Cancer (NSCLC): Utilized as a first-line treatment in combination with other agents for patients who are not candidates for curative surgery or radiation. AIDS-Related Kaposi’s Sarcoma: Employed as a specialized second-line intervention for advanced cases. The Science of PACLIEVA: Mechanism of Action Protein Binding: Paclitaxel binds specifically to the beta-tubulin subunit of the cell's microtubules. Structural Stabilization: It promotes the assembly of microtubules while simultaneously preventing their disassembly (depolymerization). Mitotic Arrest: By “freezing“ the mitotic spindle, PACLIEVA prevents the cancer cell from completing its division cycle (mitosis). Cellular Apoptosis: The resulting cell-cycle arrest triggers programmed cell death, effectively reducing tumor size and slowing the spread (metastasis) of the disease. Administration and Dosage Protocols Route: Administered exclusively via Intravenous (IV) Infusion by qualified oncology professionals. Preparation: Due to its high concentration, PACLIEVA 260 MG must be properly diluted in 0.9% Sodium Chloride or 5% Dextrose as per strict clinical guidelines. Pre-medication Protocol: To mitigate the risk of severe hypersensitivity, patients must be pre-medicated with corticosteroids, antihistamines, and H2 antagonists (e.g., Dexamethasone, Diphenhydramine, and Ranitidine). Cycle Management: The 260mg strength allows for efficient dosing in regimens typically scheduled every 3 weeks, tailored to the patient’s body surface area (BSA). Safety Profile and Clinical Monitoring Hematological Monitoring: Regular blood work is essential to track bone marrow suppression, specifically neutropenia, which is a dose-limiting factor. Neurotoxicity Vigilance: Clinicians monitor for peripheral neuropathy, often manifesting as tingling or numbness in the extremities. Infusion Reaction Monitoring: Close observation is required during the first hour of infusion for symptoms like flushing, skin reactions, or dyspnea. Hepatic Monitoring: Liver function tests (LFTs) are periodically conducted to ensure the patient can effectively metabolize the drug. Storage and Handling Instructions Storage: Keep in the original carton at room temperature (20°C to 25°C) to protect the vial from light. Cytotoxic Handling: As a hazardous antineoplastic agent, PACLIEVA should be handled using specialized safety equipment (PPE) and disposed of according to international biohazard protocols. Why Partner with Ernest Oncology for Global Exports? 100% Genuine Supply: We source products directly from GMP-certified manufacturers, guaranteeing authentic medication with optimal shelf life. Global Distribution Network: We facilitate rapid and secure shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Regulatory Expertise: Our team manages all export documentation, including Certificates of Analysis (CoA) and necessary permits, ensuring smooth customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale pricing to support hospitals, oncology centers, and pharmaceutical importers. Secure Logistics: We utilize industry-standard packaging to maintain product stability and integrity during long-distance international transit 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: [exports@ernestpharmaceuticals.com] 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

PACLIEVA 100 MG Injection (Paclitaxel): Advanced Chemotherapeutic Solution for Targeted Oncology PACLIEVA 100 MG Injection is a high-concentration antineoplastic medication containing Paclitaxel, a potent agent belonging to the taxane family of drugs. As a cornerstone of modern chemotherapy, PACLIEVA 100 MG is widely utilized in international clinical settings to combat various forms of advanced and metastatic solid tumors. Therapeutic Indications and Clinical Applications Advanced Ovarian Cancer: Used as first-line therapy (often in combination with platinum agents) and as second-line therapy for patients who have not responded to standard treatments. Metastatic Breast Cancer: Highly effective for patients where anthracycline treatment has failed or is not indicated. Non-Small Cell Lung Cancer (NSCLC): Prescribed for advanced cases in patients who are not eligible for curative surgery or radiation therapy. AIDS-Related Kaposi’s Sarcoma: Utilized as a specialized second-line treatment for patients with advanced disease. The Science of PACLIEVA: Mechanism of Action Binding to Tubulin: Paclitaxel binds specifically to the beta-tubulin subunit of the cell's microtubules. Prevention of Depolymerization: It stabilizes the microtubules and prevents them from breaking down. Mitotic Arrest: Because the microtubules cannot reorganize, the cancer cell is “locked“ in the middle of division (mitosis). Programmed Cell Death: This arrest triggers apoptosis (cell death), preventing the tumor from growing or spreading (metastasizing) further. Administration and Dosage Protocols Route: Administered solely via Intravenous (IV) Infusion by trained oncology professionals. Infusion Schedule: Typically administered over a 3-hour or 24-hour period, depending on the specific protocol (e.g., every 3 weeks or a weekly dose-dense regimen). Pre-medication Requirement: To mitigate the risk of severe hypersensitivity reactions, patients are usually pre-medicated with corticosteroids (like dexamethasone), antihistamines, and H2 antagonists. Specialized Equipment: PACLIEVA must be administered using non-PVC infusion sets and an in-line filter to ensure drug stability and patient safety. Safety Profile and Professional Monitoring Myelosuppression: Regular blood work is mandatory to monitor for neutropenia (low white blood cell count), which is the dose-limiting toxicity. Peripheral Neuropathy: Monitoring for numbness, tingling, or pain in the extremities is essential for long-term care. Infusion Reactions: Close observation during the first hour of infusion for symptoms such as dyspnea, hypotension, or angioedema. Cardiac Monitoring: While infrequent, vital signs should be monitored for bradycardia or other rhythmic disturbances. Storage and Handling Guidelines Storage: Store in the original carton at controlled room temperature (20°C to 25°C) to protect from light. Handling: As a cytotoxic drug, PACLIEVA should be handled with caution by healthcare workers using proper personal protective equipment (PPE) and following hazardous waste disposal protocols. Why Choose Ernest Oncology? Verified Authenticity: We source products directly from GMP-certified manufacturers, guaranteeing 100% genuine medication with optimal shelf life. Global Logistics Network: We specialize in rapid and secure shipping to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, Middle East, Africa, and Asia. Professional Regulatory Support: Our team handles all export documentation, Certificates of Analysis (CoA), and customs requirements for a seamless transaction. Bulk Supply Efficiency: As a bulk supplier and distributor, we provide competitive wholesale pricing for hospitals, oncology centers, and government health departments. Secure Packaging: We utilize specialized pharmaceutical-grade packaging to maintain product integrity during long-distance transit. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com www.ernestpharmaceuticals.com 📧 Email: [exports@ernestpharmaceuticals.com] 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection

PACLIEVA 30 MG Injection (Paclitaxel): Targeted Cytotoxic Therapy for Advanced Oncology PACLIEVA 30 MG Injection is a potent antineoplastic medication containing the active pharmaceutical ingredient paclitaxel. Classified as a taxane, it is one of the most widely used and effective chemotherapy agents in modern oncology. Manufactured by Zuventus Healthcare, PACLIEVA is engineered to inhibit the growth and spread of malignant cells by disrupting the cellular division process. Therapeutic Indications and Global Clinical Usage Breast Cancer: Used as both an adjuvant treatment (after surgery) and for metastatic disease, particularly in patients who have not responded to standard anthracycline therapy. Ovarian Cancer: Often used as a first-line therapy in combination with platinum agents (like cisplatin or carboplatin) for advanced carcinoma. Non-Small Cell Lung Cancer (NSCLC): Indicated for the treatment of advanced NSCLC in patients who are not candidates for potentially curative surgery or radiation therapy. Kaposi's Sarcoma: Specifically utilized for the second-line treatment of AIDS-related Kaposi's sarcoma. Mechanism of Action: How PACLIEVA 30 MG Works PACLIEVA works as a “microtubule stabilizer.“ Unlike many other chemotherapy drugs that prevent the assembly of microtubules, Paclitaxel works differently: Microtubule Stabilization: It binds to the tubulin protein within cancer cells, promoting the assembly of microtubules while preventing their disassembly. Mitotic Arrest: By “freezing“ the microtubules, PACLIEVA prevents the cancer cell from successfully completing mitosis (cell division). Apoptosis: Unable to divide, the malignant cell eventually triggers programmed cell death (apoptosis), thereby reducing tumor volume and preventing further metastasis. Dosage and Administration Guidelines Route of Administration: PACLIEVA is administered strictly via Intravenous (IV) Infusion. Pre-medication: To prevent severe hypersensitivity reactions, patients are typically pre-treated with corticosteroids, antihistamines, and H2 antagonists. Cycle Duration: The dosage and frequency depend on the specific cancer type, patient body surface area (BSA), and blood counts. It is commonly administered every 3 weeks or weekly in specific dose-dense regimens. Professional Handling: This medication must be administered by a qualified oncologist or oncology nurse in a clinical setting equipped to manage infusion-related reactions. Safety Profile and Clinical Monitoring Hematological Vigilance: Regular blood tests are essential to monitor for bone marrow suppression (neutropenia, anemia, and thrombocytopenia). Neurological Monitoring: Patients should be monitored for peripheral neuropathy (tingling or numbness in hands and feet). Hypersensitivity: Immediate monitoring for allergic reactions during the start of the infusion is mandatory. Cardiac Function: Though rare, monitoring for bradycardia or asymptomatic hypotension is recommended during administration. Storage and Global Handling Instructions Temperature: Store at controlled room temperature, 20°C to 25°C Dilution: Once diluted in a suitable IV fluid (like 0.9% Sodium Chloride or 5% Dextrose), the solution should be used within the timeframe specified by the manufacturer to ensure stability. Why source PACLIEVA 30 MG from Ernest Oncology? 100% Genuine Medication: We source PACLIEVA directly from authorized GMP-certified channels, ensuring every vial is authentic with an optimal shelf life. Global Distribution Reach: Secure and rapid export to the USA, UK, UAE, Australia, Singapore, South Africa, Europe, the Middle East, Africa, and Asia. Specialized Cold Chain/Secure Logistics: Our team manages pharmaceutical logistics with precision, utilizing secure packaging and efficient transit to preserve drug stability. Regulatory & Documentation Support: We handle all necessary export paperwork, including Certificates of Analysis (CoA) and permits, for seamless customs clearance. Bulk Supplier Advantage: As a dedicated distributor, we offer competitive wholesale rates to help hospitals and oncology centers manage specialty care costs effectively. 📞 Contact Ernest Oncology—Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 🌐 Websites www.oncologymediciensupplier.com www.ernestvision.com www.ernestpharmaceuticals.com www.ernestimpex.com 📧 Email: [exports@ernestpharmaceuticals.com] 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Direct WhatsApp Connection